ArticleJACC. Case reports2026
Successful Transcatheter Aortic Valve Implantation for Severe Stenosis of a Quadricuspid Aortic Valve.
Article in JACC. Case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundQuadricuspid aortic valve (QAV) is a rare congenital anomaly with an incidence of 0.006% to 0.05%. It often leads to aortic stenosis or regurgitation due to progressive fibrosis and calcification. While surgical aortic valve replacement has been the standard treatment, transcatheter aortic valve implantation (TAVI) is emerging as a less invasive alternative for high-risk patients. CASE SUMMARY: An 84-year-old woman with ischemic cardiomyopathy and heart failure presented with severe aortic stenosis on a calcified QAV. Given her high surgical risk (EuroSCORE II: 9.69), she underwent successful transfemoral TAVI with a 23-mm Edwards Sapien III Ultra valve. Postoperatively, she developed a left bundle branch block requiring an upgrade to cardiac resynchronization therapy with defibrillator. At the 1-year follow-up, she remained minimally symptomatic with excellent valve function. TAKE-HOME MESSAGE: TAVI is a feasible and effective option for treating severe aortic stenosis in patients with QAV, offering a viable alternative to surgery in high-risk cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.